Released: 9/15/2009
Expires: 9/15/2010

Target Audience
This activity was developed for pharmacy directors, P&T Committee members, managed care pharmacists, oncology pharmacists, and other key stakeholders who wish to enhance their knowledge concerning the implementation of a value-based benefit design for cancer care.

Learning Objectives
At the completion of this activity participants should be able to:

• Provide payers with a practical understanding of the key clinical, business, and regulatory factors, guidelines, and research advances involving breast cancer treatment that providers are using as the basis for their treatment decisions
• Offer payers a multistakeholder commentary on this information, to identify the impact on different stakeholders of these changes to treatment
• Illuminate the different perspectives and incentives of the various stakeholders involved in breast cancer treatment decisions: patients, providers, payers, purchasers, distributors, regulatory agencies, and manufacturers
• Align incentives with providers and transform payer drug management policies into patient-centered, value based models

Pharmacists Designation
Medical Learning Institute, Inc., is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 468-999-09-032-H01-P.

Instructions for Credit
There is no fee for this activity. To receive credit, participants must first take the pretest for this activity. After reading this CE activity in its entirety, participants must complete the posttest and evaluation. The pretest, posttest, and evaluation can be completed online at www.mlicme.org/p09049.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the accreditation of this activity, please contact Medical Learning Institute at (609) 333-1693 or cgusack@mlicme.org.

Disclosure Statement
Before the activity, all faculty will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions.

The associates of Medical Learning Institute, Inc., and Center of Excellence Media, LLC, have no financial relationships to disclose.

Dr Owens is a consultant to AstraZeneca, Genentech, and Wyeth, and is on the advisory board of ImClone Systems, Roche, and sanofi-aventis.

Faculty Disclosures
Gary Owens, MD is a consultant for Amgen, AstraZeneca, Centocor-Ortho Biotech, Eli Lilly, Novartis, and Schering Plough , and is on the advisory board for Imclone Systems, Roche, and sanofi-aventis.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.